<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Int Med</journal-id><journal-id journal-id-type="iso-abbrev">J Transl Int Med</journal-id><journal-id journal-id-type="publisher-id">jtim</journal-id><journal-id journal-id-type="pmc">jtim</journal-id><journal-title-group><journal-title>Journal of Translational Internal Medicine</journal-title></journal-title-group><issn pub-type="ppub">2450-131X</issn><issn pub-type="epub">2224-4018</issn><publisher><publisher-name>Sciendo</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">jtim-2019-0028</article-id><article-id pub-id-type="doi">10.2478/jtim-2019-0028</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Influenza Vaccination and Guillain&#x02013;Barr&#x000e9; Syndrome: Reality or Fear</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Babazadeh</surname><given-names>Arefeh</given-names></name><xref ref-type="aff" rid="j_jtim-2019-0028_aff_001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mohseni Afshar</surname><given-names>Zeinab</given-names></name><xref ref-type="aff" rid="j_jtim-2019-0028_aff_002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Javanian</surname><given-names>Mostafa</given-names></name><xref ref-type="aff" rid="j_jtim-2019-0028_aff_001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mohammadnia-Afrouzi</surname><given-names>Mousa</given-names></name><xref ref-type="aff" rid="j_jtim-2019-0028_aff_001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Karkhah</surname><given-names>Ahmad</given-names></name><xref ref-type="aff" rid="j_jtim-2019-0028_aff_003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Masrour-Roudsari</surname><given-names>Jila</given-names></name><xref ref-type="aff" rid="j_jtim-2019-0028_aff_001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sabbagh</surname><given-names>Parisa</given-names></name><xref ref-type="aff" rid="j_jtim-2019-0028_aff_001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Koppolu</surname><given-names>Veerendra</given-names></name><xref ref-type="aff" rid="j_jtim-2019-0028_aff_004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vasigala</surname><given-names>Veneela KrishnaRekha</given-names></name><xref ref-type="aff" rid="j_jtim-2019-0028_aff_005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ebrahimpour</surname><given-names>Soheil</given-names></name><xref ref-type="aff" rid="j_jtim-2019-0028_aff_001"><sup>1</sup></xref><xref ref-type="corresp" rid="jtim-2019-0028_cor_001">*</xref></contrib><aff id="j_jtim-2019-0028_aff_001"><label>1</label><institution content-type="dept">Infectious Diseases and Tropical Medicine Research Center</institution>, <institution>Health Research Institute</institution>, <institution content-type="university">Babol University of Medical Sciences</institution>, <city>Babol</city>, I.R. Iran<country country="IR"/></aff><aff id="j_jtim-2019-0028_aff_002"><label>2</label><institution content-type="dept">Clinical Research Development Center</institution>, <institution>Imam Reza Hospital</institution>, <institution content-type="university">Kermanshah University of Medical Sciences</institution>, <city>Kermanshah</city>, Iran<country country="IR"/></aff><aff id="j_jtim-2019-0028_aff_003"><label>3</label><institution content-type="dept">Student Research Committee, School of Medicine</institution>, <institution content-type="university">Babol University of Medical Sciences</institution>, <city>Babol</city>, Iran<country country="IR"/></aff><aff id="j_jtim-2019-0028_aff_004"><label>4</label><institution content-type="dept">Scientist Biopharmaceutical Development Medimmune Gaithersburg</institution><institution content-type="private"/>, MD <addr-line>20878</addr-line>, USA<country country="US"/></aff><aff id="j_jtim-2019-0028_aff_005"><label>5</label><institution>Rangaraya Medical College</institution>, <institution content-type="university">NTR University of Health Sciences</institution>, <city>Kakinada</city>, <country country="IN">India</country></aff></contrib-group><author-notes><corresp id="jtim-2019-0028_cor_001"><label>*</label> E-mail: <email xlink:href="mailto:Drsoheil1503@yahoo.com">Drsoheil1503@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><month>12</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>31</day><month>12</month><year>2019</year></pub-date><volume>7</volume><issue>4</issue><fpage>137</fpage><lpage>142</lpage><permissions><copyright-statement>&#x000a9; 2019 Arefeh Babazadeh et al., published by Sciendo</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Arefeh Babazadeh et al., published by Sciendo</copyright-holder><license license-type="open-access" specific-use="rights-object-archive-dnb" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0"><license-p>This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.</license-p></license></permissions><abstract><title>Abstract</title><p>Guillain&#x02013;Barr&#x000e9; syndrome (GBS) is an inflammatory disorder and an acute immune-mediated demyelinating neuropathy that causes reduced signal transmissions, progressive muscle weakness, and paralysis. The etiology of the syndrome still remains controversial and uncertain. GBS can be initiated and triggered by respiratory tract infections such as influenza, and intestinal infections such as <italic>Campylobacter jejuni</italic>. In addition, there is considerable evidence suggesting links between influenza vaccination and GBS. As reported previously, the incidence of GBS in individuals receiving swine flu vaccine was about one to two cases per million. Despite the influenza vaccine efficacy, its association with an immune-mediated demyelinating process can be challenging as millions of people get vaccinated every year. In this review we will discuss the association between influenza infection and vaccination with GBS by focusing on the possible immunopathological mechanisms.</p></abstract><kwd-group><title>Keywords</title><kwd>influenza</kwd><kwd>flu vaccination</kwd><kwd>Guillain&#x02013;Barr&#x000e9; syndrome</kwd></kwd-group><counts><page-count count="6"/></counts></article-meta></front><body><sec id="j_jtim-2019-0028_s_001"><title>INTRODUCTION</title><p>Guillain&#x02013;Barr&#x000e9; syndrome (GBS) is a rare immune disorder in which the immune system invades Schwann cells of the peripheral nervous system (PNS).<sup>[<xref rid="j_jtim-2019-0028_ref_001" ref-type="bibr">1</xref>,<xref rid="j_jtim-2019-0028_ref_002" ref-type="bibr">2</xref>,<xref rid="j_jtim-2019-0028_ref_003" ref-type="bibr">3</xref>]</sup> The etiology of GBS is still unclear. Recent investigations demonstrated that GBS can be triggered by several respiratory tract and intestinal infections. A significant number of GBS cases were also inflicted by Zika virus infection. After a large-scale vaccination campaign in 1976 against swine influenza, an increase in the incidence of GBS was noticed and thus raising the doubts on the safety of influenza vaccination.<sup>[<xref rid="j_jtim-2019-0028_ref_004" ref-type="bibr">4</xref>]</sup> Subsequently, many studies were performed to evaluate the association of infections and in particular influenza as well as influenza vaccination with an incidence of GBS.</p></sec><sec id="j_jtim-2019-0028_s_002"><title>GUILLAIN&#x02013;BARR&#x000c9; SYNDROME: SYMPTOMS AND CAUSES</title><p>Since the eradication of polio, GBS has become the most common cause of acute flaccid paralysis. GBS is an autoimmune disorder affecting the Schwann cells of the PNS. This immune-mediated demyelinating neuropathy can rapidly evolve over a period of few days or more and can lead to paralysis or even death.<sup>[<xref rid="j_jtim-2019-0028_ref_005" ref-type="bibr">5</xref>,<xref rid="j_jtim-2019-0028_ref_006" ref-type="bibr">6</xref>,<xref rid="j_jtim-2019-0028_ref_007" ref-type="bibr">7</xref>]</sup> The initial symptoms of GBS include muscle weakness that starts from distal limbs which subsequently progresses to proximal limbs.<sup>[<xref rid="j_jtim-2019-0028_ref_008" ref-type="bibr">8</xref>]</sup> GBS may lead to respiratory failure requiring mechanical ventilation over 15% of cases.<sup>[<xref rid="j_jtim-2019-0028_ref_009" ref-type="bibr">9</xref>]</sup> In some cases, GBS can affect the heart rate and changes the blood pressure by disrupting the autonomic nervous system.<sup>[<xref rid="j_jtim-2019-0028_ref_010" ref-type="bibr">10</xref>]</sup> The disease can be self-limiting, with muscle strength reaching a lowest point in few days, followed by a partial or full recovery over weeks to months. Diagnosis of this syndrome is based on the clinical signs and symptoms and through rule out of other differential diagnoses as shown in <xref rid="j_jtim-2019-0028_tab_001" ref-type="table">Table 1</xref>. The treatment includes administration of intravenous immunoglobulins or plasmapheresis, and supportive therapies. Although most people have an uneventful recovery, up to one-third of the cases are left with severe neurological deficits.<sup>[<xref rid="j_jtim-2019-0028_ref_011" ref-type="bibr">11</xref>, <xref rid="j_jtim-2019-0028_ref_012" ref-type="bibr">12</xref>]</sup> The mortality rate of the disease is approximately 8% in developing world, but much lower in developed countries.<sup>[<xref rid="j_jtim-2019-0028_ref_013" ref-type="bibr">13</xref>]</sup> The incidence of GBS increases with age, and people older than 50 years are at greatest risk for developing GBS. The estimated risk of developing GBS in the world is one to two cases per 100,000 people per year.<sup>[<xref rid="j_jtim-2019-0028_ref_014" ref-type="bibr">14</xref>]</sup> Severe autoimmune responses resulted from infections by external infectious agents are considered as major initiating factors of the syndrome.<sup>[<xref rid="j_jtim-2019-0028_ref_015" ref-type="bibr">15</xref>, <xref rid="j_jtim-2019-0028_ref_016" ref-type="bibr">16</xref>]</sup> Infection by <italic>Campylobacter jejuni</italic> is identified as the most common inciting event although other agents such as herpes simplex virus (HSV), cytomegalovirus (CMV), Epstein&#x02013;Barr virus (EBV), Zika virus (ZIKV), <italic>Mycoplasma pneumoniae, Haemophilus influenza</italic>, and influenza have been reported.<sup>[<xref rid="j_jtim-2019-0028_ref_007" ref-type="bibr">7</xref>, <xref rid="j_jtim-2019-0028_ref_017" ref-type="bibr">17</xref>,<xref rid="j_jtim-2019-0028_ref_018" ref-type="bibr">18</xref>,<xref rid="j_jtim-2019-0028_ref_019" ref-type="bibr">19</xref>,<xref rid="j_jtim-2019-0028_ref_020" ref-type="bibr">20</xref>,<xref rid="j_jtim-2019-0028_ref_021" ref-type="bibr">21</xref>,<xref rid="j_jtim-2019-0028_ref_022" ref-type="bibr">22</xref>]</sup> Vaccination to influenza has been implicated in GBS, although the evidence for this link is controversial.<sup>[<xref rid="j_jtim-2019-0028_ref_023" ref-type="bibr">23</xref>]</sup></p><table-wrap id="j_jtim-2019-0028_tab_001" orientation="portrait" position="float"><label>Table 1</label><caption><p>Some diagnostic criteria in Guillain&#x02013;Barr&#x000e9; syndrome.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="left" valign="bottom" rowspan="1"><bold>Criteria for diagnosis of Guillain&#x02013;Barr&#x000e9; syndrome</bold></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="2" colspan="1"><bold>Required</bold></td><td align="left" valign="middle" rowspan="1" colspan="1">Weakness within 4 weeks from onset of syndrome (starting muscle weakness in lower limbs)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hyporeflexia</td></tr><tr><td align="left" valign="middle" rowspan="3" colspan="1"><bold>Supportive</bold></td><td align="left" valign="middle" rowspan="1" colspan="1">Lack of fever in the patient</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Infections of the respiratory and gastrointestinal system during the past few weeks</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Increased protein concentration in cerebrospinal fluid (CSF) with moderate increase in the cell</td></tr></tbody></table></table-wrap></sec><sec id="j_jtim-2019-0028_s_003"><title>IMMUNOPATHOLOGY OF GUILLAIN&#x02013;BARR&#x000c9; SYNDROME</title><p>Access to the PNS by the immune system requires crossing of the blood&#x02013;nerve barrier. The blood&#x02013;nerve barrier is not as tight as the blood&#x02013;brain barrier, so that small amounts of circulating proteins and immunoglobulin G (IgG) can leak into PNS making it vulnerable to the immune attacks. The blood&#x02013;nerve barrier is particularly leaky within the dorsal root ganglia and is altogether absent at nerve terminals, making these areas especially vulnerable to immune-mediated attacks. As previously mentioned, GBS begins with infectious agents such as influenza virus. Antigen-presenting cells (APCs) including dendritic cells (DCs), macrophages, and B lymphocytes are in the frontline dealing with the influenza infections.<sup>[<xref rid="j_jtim-2019-0028_ref_024" ref-type="bibr">24</xref>, <xref rid="j_jtim-2019-0028_ref_025" ref-type="bibr">25</xref>]</sup> Epitopes displayed by the virus interact with pattern recognition receptors (PRRs) on APCs, especially DCs. Stimulation of APCs results in T cell activation and differentiation into either a Th1 (T helper cell type 1) or Th2 phenotype. Each phenotype has its specific cytokine signature and function. Once inside the PNS, the Th1 phenotype of differentiated Th cell recruits and activates macrophages. Macrophages initiate damage to PNS by producing and secreting matrix metalloproteinases (MMPs) and nitric oxide.<sup>[<xref rid="j_jtim-2019-0028_ref_026" ref-type="bibr">26</xref>]</sup> Humoral responses are initiated through activation of B cells by Th2 lymphocytes or by the epitopes of the virus cross-linking the B cell receptors. Both these pathways can result in class switching of activated B cells to IgG-producing plasma cells. The secreted IgG binds to viral surface epitopes and cross-reacts with similar epitopes in the peripheral nervous tissues. These antigen&#x02013;antibody interactions can activate the complement system, resulting in membrane attack complex (MAC) formation <sup>[<xref rid="j_jtim-2019-0028_ref_027" ref-type="bibr">27</xref>]</sup> leading to nerve cell membrane damage and destruction.<sup>[<xref rid="j_jtim-2019-0028_ref_028" ref-type="bibr">28</xref>]</sup></p></sec><sec id="j_jtim-2019-0028_s_004"><title>INFLUENZA AND ITS COMPLICATIONS</title><p>Influenza is a highly contagious respiratory infection that is common in cold seasons.<sup>[<xref rid="j_jtim-2019-0028_ref_029" ref-type="bibr">29</xref>]</sup> Annually, influenza epidemics cause 3&#x02013;5 million severe cases of hospitalization and 300,000&#x02013;600,000 deaths.<sup>[<xref rid="j_jtim-2019-0028_ref_030" ref-type="bibr">30</xref>, <xref rid="j_jtim-2019-0028_ref_031" ref-type="bibr">31</xref>]</sup></p><p>Typical symptoms of influenza infection include fever with shaking chills, myalgia, fatigue, anorexia, and diarrhea. The severity of these symptoms and their sudden occurrence can help differentiate influenza from other respiratory viral infections.<sup>[<xref rid="j_jtim-2019-0028_ref_029" ref-type="bibr">29</xref>,<xref rid="j_jtim-2019-0028_ref_032" ref-type="bibr">32</xref>,<xref rid="j_jtim-2019-0028_ref_033" ref-type="bibr">33</xref>]</sup> Symptoms such as cough and sore throat are prevalent in influenza; however symptoms such as coryza are more due to common cold infections than influenza infection.<sup>[<xref rid="j_jtim-2019-0028_ref_034" ref-type="bibr">34</xref>]</sup> Influenza viruses are divided into influenza A, B, and C types. Influenza A and B viruses circulate in the community in the winter every year and are found to be responsible for seasonal epidemics.<sup>[<xref rid="j_jtim-2019-0028_ref_035" ref-type="bibr">35</xref>]</sup> Influenza C viruses usually have no symptoms or show mild symptoms and do not cause epidemics.<sup>[<xref rid="j_jtim-2019-0028_ref_036" ref-type="bibr">36</xref>]</sup> Mutations in the influenza viral genomes leading to antigen changes (shift or drift), as well as the existence of animal reservoirs, can make the influenza treatment challenging as public immunity from previous immunizations may not be enough for protection.<sup>[<xref rid="j_jtim-2019-0028_ref_037" ref-type="bibr">37</xref>]</sup> In some instances the changes to the viral genomes are so intense that the existing vaccines may no longer be effective leading to pandemics, such as a late winter outbreak of swine flu (pH1N1) in 1976 and flu pandemic or swine flu in 2009 (caused by influenza A virus type pH1N1).<sup>[<xref rid="j_jtim-2019-0028_ref_038" ref-type="bibr">38</xref>]</sup> The complications of influenza infection can be either mild or very severe. Sinusitis and otitis are examples of moderate complications of influenza.<sup>[<xref rid="j_jtim-2019-0028_ref_039" ref-type="bibr">39</xref>]</sup> Serious complications include viral pneumonitis, secondary bacterial pneumonia (<italic>Staphylococcus aureus</italic> pneumonia or <italic>Streptococcus pneumoniae</italic>),<sup>[<xref rid="j_jtim-2019-0028_ref_039" ref-type="bibr">39</xref>, <xref rid="j_jtim-2019-0028_ref_040" ref-type="bibr">40</xref>]</sup> myocarditis, encephalitis, myositis or rhabdomyolysis, GBS, and multiple organ failures.<sup>[<xref rid="j_jtim-2019-0028_ref_041" ref-type="bibr">41</xref>,<xref rid="j_jtim-2019-0028_ref_042" ref-type="bibr">42</xref>,<xref rid="j_jtim-2019-0028_ref_043" ref-type="bibr">43</xref>]</sup></p></sec><sec id="j_jtim-2019-0028_s_005"><title>INFLUENZA VACCINES AND ADVERSE EFFECTS</title><p>Influenza vaccines are commonly available for seasonal influenza and new versions of the vaccines are developed every year as the virus rapidly changes. Pandemic influenza vaccines are produced against certain strains of the influenza virus, such as the 2009 pH1N1 virus for rapid distribution during an influenza pandemic.<sup>[<xref rid="j_jtim-2019-0028_ref_044" ref-type="bibr">44</xref>]</sup> Flu vaccines are available either as injectable inactivated vaccines or nasal spray flu vaccines (live attenuated influenza vaccine).<sup>[<xref rid="j_jtim-2019-0028_ref_045" ref-type="bibr">45</xref>, <xref rid="j_jtim-2019-0028_ref_046" ref-type="bibr">46</xref>]</sup> Some resources report that injectable trivalent and quadrivalent inactivated influenza vaccines are frequently used globally. Serious side effects to the flu vaccination are not very common. The most common adverse effects include pain at the injection site, muscle aches, fever, and malaise.<sup>[<xref rid="j_jtim-2019-0028_ref_047" ref-type="bibr">47</xref>, <xref rid="j_jtim-2019-0028_ref_048" ref-type="bibr">48</xref>]</sup> Allergic reactions have also been rarely reported.<sup>[<xref rid="j_jtim-2019-0028_ref_049" ref-type="bibr">49</xref>]</sup> GBS after influenza vaccination was first reported in 1976, which has become the origin of numerous studies on the association between this neurological disease and the vaccine.<sup>[<xref rid="j_jtim-2019-0028_ref_050" ref-type="bibr">50</xref>, <xref rid="j_jtim-2019-0028_ref_051" ref-type="bibr">51</xref>]</sup> Before that, GBS was only associated with infectious diseases, but since 1976 an increase in the incidence of GBS after influenza vaccination has been noted with the same antigenic similarity in the role of vaccines, especially the influenza vaccine.</p></sec><sec id="j_jtim-2019-0028_s_006"><title>INFLUENZA VACCINE AND GUILLAIN&#x02013;BARR&#x000c9; SYNDROME</title><p>Incidence of GBS after influenza vaccination was first reported in 1976 during a national vaccination program against pandemic swine flu in the United States.<sup>[<xref rid="j_jtim-2019-0028_ref_050" ref-type="bibr">50</xref>, <xref rid="j_jtim-2019-0028_ref_051" ref-type="bibr">51</xref>]</sup> About 40 million people were vaccinated with the influenza A vaccine (influenza A vaccine in New Jersey) during the pandemic, and subsequently an eight-times increase in GBS incidence was observed (especially at 2&#x02013;3 weeks or even more after vaccination).<sup>[<xref rid="j_jtim-2019-0028_ref_052" ref-type="bibr">52</xref>]</sup> Since then, many researches evaluated the risk of GBS after receiving the seasonal and pandemic inactivated influenza vaccine. An overview conducted on 39 studies reported that the relative risk of GBS after pandemic influenza vaccination was higher than that after seasonal influenza vaccination, with an overall relative risk for the incidence of GBS after influenza vaccination was 1.4 (95% CI: 1.2&#x02013;1.7).<sup>[<xref rid="j_jtim-2019-0028_ref_004" ref-type="bibr">4</xref>]</sup> Other studies investigating the association between GBS and seasonal influenza vaccines after 1976 indicated the risk as very minimal with less than one case per million.<sup>[<xref rid="j_jtim-2019-0028_ref_053" ref-type="bibr">53</xref>]</sup> Risk of GBS is maximum in the first 2&#x02013;3 weeks post vaccination, but in most cases the estimated risk was one to two cases per million vaccinations.<sup>[<xref rid="j_jtim-2019-0028_ref_054" ref-type="bibr">54</xref>, <xref rid="j_jtim-2019-0028_ref_055" ref-type="bibr">55</xref>]</sup> Furthermore, the biologic mechanism for GBS following influenza vaccine may involve the synergistic effects of endotoxins and vaccine induced autoimmunity. Following the H1N1 influenza pandemic in 2009 and the administration of the pH1N1 monovalent vaccine due to its similarity to the H1N1 monovalent vaccine in 1976, there were concerns about the probability of GBS. However, the studies that investigated this issue estimated the attributable risk to be about one to five per million doses of vaccination. In a meta-analysis conducted following the 2009 H1N1 monovalent influenza vaccination program (the largest nationwide vaccination program in the United States), the incidence of GBS was reported as 1.6 cases per million vaccinated people, which is approximately equal to the attributable risk reported for the seasonal influenza vaccination. Therefore, there is currently no consensus on the prohibition of the administration of the influenza vaccine. Nonetheless, it was recommended that caution should be taken in the revaccination of persons who have developed GBS within 6 weeks after receiving the influenza vaccine.</p></sec><sec id="j_jtim-2019-0028_s_007"><title>INFLUENZA AND GUILLAIN&#x02013;BARR&#x000c9; SYNDROME</title><p>Even before the term &#x0201c;Guillain&#x02013;Barr&#x000e9; syndrome&#x0201d; was used in the clinical medicine, cases of infectious polyneuritis have been reported during influenza pandemic in the early twentieth century. About two-thirds of the influenza-infected patients initially present respiratory or gastrointestinal tract infections. Two studies in England (2007 and 2009) reported a strong association between influenza infection and GBS, with GBS occurring within 3 months after the influenza-like illness (ILI).<sup>[<xref rid="j_jtim-2019-0028_ref_023" ref-type="bibr">23</xref>]</sup> In further strengthening the association of influenza infection to GBS, another study conducted on GBS patients confirmed a prior influenza infection.<sup>[<xref rid="j_jtim-2019-0028_ref_056" ref-type="bibr">56</xref>]</sup> The relative incidence of GBS after influenza was highest in the first week after infection and decreased during the next 6 weeks. The estimated risk of GBS after influenza was reported as 17.2 cases per 1 million patients hospitalized with influenza.<sup>[<xref rid="j_jtim-2019-0028_ref_057" ref-type="bibr">57</xref>]</sup> A study in Norway during the 2009 pandemic (H1N1) influenza showed a much higher GBS in influenza patients with a relative risk of 4.89 (95% CI: 1.7&#x02013;20.36). The risk of incidence of GBS post influenza infection was also higher than the relative risk of 1.1 (95% CI: 0.51&#x02013;2.43) reported for pH1N1 vaccination.<sup>[<xref rid="j_jtim-2019-0028_ref_058" ref-type="bibr">58</xref>]</sup></p></sec><sec id="j_jtim-2019-0028_s_008"><title>GUILLAIN&#x02013;BARR&#x000c9; SYNDROME, INFLUENZA VIRUS INFECTION, AND INFLUENZA VACCINE</title><p>According to several studies, there has been no proven association between the incidence of GBS and influenza vaccination with the exception of 1976 H1N1 influenza vaccination campaign in New Jersey.<sup>[<xref rid="j_jtim-2019-0028_ref_059" ref-type="bibr">59</xref>]</sup> In fact 1976 H1N1 influenza vaccine in New Jersey is the only proven association of GBS and influenza vaccination. A study that analyzed few cases of GBS or Miller Fisher syndrome reported that the increase in the incidence of GBS syndrome was unlikely to occur over 40 days after vaccination.<sup>[<xref rid="j_jtim-2019-0028_ref_060" ref-type="bibr">60</xref>]</sup> These studies suggest that the proven association between influenza vaccines and GBS is very little, and most often occurs in the case of pandemic vaccines. It seems that no prohibition can be considered for administration of influenza vaccine, except in persons who have had a history of GBS within 6 weeks after vaccination. On the other hand, some studies have noted seasonal winter patterns for GBS incidence.<sup>[<xref rid="j_jtim-2019-0028_ref_061" ref-type="bibr">61</xref>]</sup> A study that examined the seasonal pattern of GBS for the year 2009 reported that an increase in vaccination coverage from 19.7% to 35.5% resulted in no similar increase in GBS cases.<sup>[<xref rid="j_jtim-2019-0028_ref_062" ref-type="bibr">62</xref>]</sup> Some other studies revealed that influenza cases increased during 2004&#x02013;2005 exactly overlapping with the wave of hospitalization due to GBS during the same period.<sup>[<xref rid="j_jtim-2019-0028_ref_063" ref-type="bibr">63</xref>]</sup> These findings suggest a significant association between hospitalization due to GBS and influenza cases, but the coverage of influenza vaccine did not significantly affect the pattern of GBS incidence in the general population.</p></sec><sec id="j_jtim-2019-0028_s_009"><title>CONCLUSION</title><p>Given the very strong association between influenza infection and the incidence of GBS, and considering the requirement of vaccination in the prevention of influenza, we should not deprive the general population from getting vaccinated on the grounds of risk for GBS due to vaccination. It is to be noted that preventing the complications of influenza is one of the important benefits of the influenza vaccine. In fact, the complication of GBS due to vaccination is a rare event and thus poses very minimal risk. Therefore educational programs are required to erase this fear from the general public opinion.</p></sec></body><back><ack id="j_jtim-2019-0028_ack_001"><title>ACKNOWLEDGMENTS</title><p>The authors would like to thank the department of infectious diseases at Babol University of Medical sciences, Iran, and also Mrs. Marzieh Nourollahzadeh for her kind and valuable comments during the study.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Conflict of Interest</bold></p><p>There are no conflicts of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="j_jtim-2019-0028_ref_001"><label>1</label><element-citation publication-type="journal" publication-format="print"><name><surname>Goodfellow</surname><given-names>JA</given-names></name><name><surname>Willison</surname><given-names>HJ</given-names></name><article-title>Guillain&#x02013;Barr&#x000e9; syndrome: a century of progress</article-title><source>Nat Rev Neurol</source><year>2016</year><volume>12</volume><fpage>723</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">27857121</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_002"><label>2</label><element-citation publication-type="journal" publication-format="print"><name><surname>Jasti</surname><given-names>AK</given-names></name><name><surname>Selmi</surname><given-names>C</given-names></name><name><surname>Sarmiento-Monroy</surname><given-names>JC</given-names></name><name><surname>Vega</surname><given-names>DA</given-names></name><name><surname>Anaya</surname><given-names>J-M</given-names></name><name><surname>Gershwin</surname><given-names>ME</given-names></name><article-title>Guillain-Barr&#x000e9; syndrome: causes, immunopathogenic mechanisms and treatment</article-title><source>Expert Rev Clin Immunol</source><year>2016</year><volume>12</volume><fpage>1175</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">27292311</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_003"><label>3</label><element-citation publication-type="journal" publication-format="print"><name><surname>Tandel</surname><given-names>H</given-names></name><name><surname>Vanza</surname><given-names>J</given-names></name><name><surname>Pandya</surname><given-names>N</given-names></name><name><surname>Jani</surname><given-names>P</given-names></name><article-title>Guillain-barr&#x000e9; syndrome (GBS)</article-title><source>A Review</source><year>2016</year><fpage>366</fpage><lpage>71</lpage></element-citation></ref><ref id="j_jtim-2019-0028_ref_004"><label>4</label><element-citation publication-type="journal" publication-format="print"><name><surname>Galeotti</surname><given-names>F</given-names></name><name><surname>Massari</surname><given-names>M</given-names></name><name><surname>D&#x02019;Alessandro</surname><given-names>R</given-names></name><name><surname>Beghi</surname><given-names>E</given-names></name><name><surname>Chi&#x000f2;</surname><given-names>A</given-names></name><name><surname>Logroscino</surname><given-names>G</given-names></name><etal/><article-title>Risk of Guillain-Barr&#x000e9; syndrome after 2010&#x02013;2011 influenza vaccination</article-title><source>Eur J Epidemiol</source><year>2013</year><volume>28</volume><fpage>433</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">23543123</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_005"><label>5</label><element-citation publication-type="journal" publication-format="print"><name><surname>Wang</surname><given-names>YZ</given-names></name><name><surname>Lv</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>QG</given-names></name><name><surname>Fan</surname><given-names>XT</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Yi Wong</surname><given-names>AH</given-names></name><etal/><article-title>Action mechanism of corticosteroids to aggravate Guillain-Barr&#x000e9; syndrome</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>13931</fpage><pub-id pub-id-type="pmid">26355080</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_006"><label>6</label><element-citation publication-type="journal" publication-format="print"><name><surname>Dimachkie</surname><given-names>MM</given-names></name><name><surname>Barohn</surname><given-names>RJ</given-names></name><article-title>Guillain-Barr&#x000e9; Syndrome and Variants</article-title><source>Neurol Clin</source><year>2013</year><volume>31</volume><fpage>491</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">23642721</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_007"><label>7</label><element-citation publication-type="journal" publication-format="print"><name><surname>Karkhah</surname><given-names>A</given-names></name><name><surname>Nouri</surname><given-names>HR</given-names></name><name><surname>Javanian</surname><given-names>M</given-names></name><name><surname>Koppolu</surname><given-names>V</given-names></name><name><surname>Masrour-Roudsari</surname><given-names>J</given-names></name><name><surname>Kazemi</surname><given-names>S</given-names></name><etal/><article-title>Zika virus: epidemiology, clinical aspects, diagnosis, and control of infection</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2018</year><volume>37</volume><fpage>2035</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">30167886</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_008"><label>8</label><element-citation publication-type="journal" publication-format="print"><name><surname>Green</surname><given-names>C</given-names></name><name><surname>Baker</surname><given-names>T</given-names></name><name><surname>Subramaniam</surname><given-names>A</given-names></name><article-title>Predictors of respiratory failure in patients with Guillain&#x02013;Barr&#x000e9; syndrome: a systematic review and meta-analysis</article-title><source>Med J Aust</source><year>2018</year><volume>208</volume><fpage>181</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">29490222</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_009"><label>9</label><element-citation publication-type="journal" publication-format="print"><name><surname>Kalita</surname><given-names>J</given-names></name><name><surname>Ranjan</surname><given-names>A</given-names></name><name><surname>Misra</surname><given-names>UK</given-names></name><article-title>Outcome of Guillain-Barre syndrome patients with respiratory paralysis</article-title><source>QJM</source><year>2016</year><volume>109</volume><fpage>319</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">26475599</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_010"><label>10</label><element-citation publication-type="journal" publication-format="print"><name><surname>Netto</surname><given-names>AB</given-names></name><name><surname>Taly</surname><given-names>AB</given-names></name><name><surname>Kulkarni</surname><given-names>GB</given-names></name><name><surname>Rao</surname><given-names>UGS</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><article-title>Mortality in mechanically ventilated patients of Guillain Barr&#x000e9; Syndrome</article-title><source>Ann Indian Acad Neurol</source><year>2011</year><volume>14</volume><fpage>262</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">22346014</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_011"><label>11</label><element-citation publication-type="journal" publication-format="print"><name><surname>Buzzigoli</surname><given-names>SB</given-names></name><name><surname>Genovesi</surname><given-names>M</given-names></name><name><surname>Lambelet</surname><given-names>P</given-names></name><name><surname>Logi</surname><given-names>C</given-names></name><name><surname>Raffaelli</surname><given-names>S</given-names></name><name><surname>Cattano</surname><given-names>D</given-names></name><article-title>Plasmapheresis treatment in Guillain-Barre syndrome: potential benefit over intravenous immunoglobulin</article-title><source>Anaesth Intensive Care</source><year>2010</year><volume>38</volume><fpage>387</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20369779</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_012"><label>12</label><element-citation publication-type="journal" publication-format="print"><name><surname>Hughes</surname><given-names>RA</given-names></name><name><surname>Swan</surname><given-names>AV</given-names></name><name><surname>van Doorn</surname><given-names>PA</given-names></name><article-title>Intravenous immunoglobulin for Guillain-Barre syndrome</article-title><source>Cochrane Database Syst Rev</source><year>2014</year><fpage>Cd002063</fpage><pub-id pub-id-type="pmid">25238327</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_013"><label>13</label><element-citation publication-type="journal" publication-format="print"><name><surname>Rocha</surname><given-names>MS</given-names></name><name><surname>Brucki</surname><given-names>SM</given-names></name><name><surname>Carvalho</surname><given-names>AA</given-names></name><name><surname>Lima</surname><given-names>UW</given-names></name><article-title>Epidemiologic features of Guillain-Barre syndrome in Sao Paulo, Brazil</article-title><source>Arq Neuropsiquiatr</source><year>2004</year><volume>62</volume><fpage>33</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15122430</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_014"><label>14</label><element-citation publication-type="journal" publication-format="print"><name><surname>Sejvar</surname><given-names>JJ</given-names></name><name><surname>Baughman</surname><given-names>AL</given-names></name><name><surname>Wise</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>OW</given-names></name><article-title>Population Incidence of Guillain-Barr&#x000e9; Syndrome: A Systematic Review and Meta-Analysis</article-title><source>Neuroepidemiology</source><year>2011</year><volume>36</volume><fpage>123</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">21422765</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_015"><label>15</label><element-citation publication-type="journal" publication-format="print"><name><surname>Harms</surname><given-names>M</given-names></name><article-title>Inpatient Management of Guillain-Barr&#x000e9; Syndrome</article-title><source>Neurohospitalist</source><year>2011</year><volume>1</volume><fpage>78</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">23983841</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_016"><label>16</label><element-citation publication-type="journal" publication-format="print"><name><surname>Greene</surname><given-names>SK</given-names></name><name><surname>Rett</surname><given-names>MD</given-names></name><name><surname>Vellozzi</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Kulldorff</surname><given-names>M</given-names></name><name><surname>Marcy</surname><given-names>SM</given-names></name><etal/><article-title>Guillain-Barre Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009&#x02013;2011</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e67185</fpage><pub-id pub-id-type="pmid">23840621</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_017"><label>17</label><element-citation publication-type="journal" publication-format="print"><name><surname>Hughes</surname><given-names>R</given-names></name><article-title>Campylobacter jejuni in Guillain-Barre syndrome</article-title><source>Lancet Neurol</source><year>2004</year><volume>3</volume><fpage>644</fpage><pub-id pub-id-type="pmid">15488456</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_018"><label>18</label><element-citation publication-type="journal" publication-format="print"><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Choe</surname><given-names>K-W</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Yoon</surname><given-names>D</given-names></name><name><surname>Ock</surname><given-names>C-Y</given-names></name><name><surname>Hong</surname><given-names>SW</given-names></name><etal/><article-title>Mild form of Guillain-Barr&#x000e9; syndrome in a patient with primary Epstein-Barr virus infection</article-title><source>Korean J Intern Med</source><year>2016</year><volume>31</volume><fpage>1191</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">26837010</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_019"><label>19</label><element-citation publication-type="journal" publication-format="print"><name><surname>Merzkani</surname><given-names>M</given-names></name><name><surname>Israel</surname><given-names>E</given-names></name><name><surname>Sachdeva</surname><given-names>M</given-names></name><article-title>Primary Cytomegalovirus Infection Causing Guillain-Barr&#x000e9; Syndrome in a Living Renal Allograft Recipient</article-title><source>Case Rep Transplant</source><year>2017</year><volume>2017</volume><comment>7264793</comment></element-citation></ref><ref id="j_jtim-2019-0028_ref_020"><label>20</label><element-citation publication-type="journal" publication-format="print"><name><surname>Ntziora</surname><given-names>F</given-names></name><name><surname>Euthimiou</surname><given-names>A</given-names></name><name><surname>Tektonidou</surname><given-names>M</given-names></name><name><surname>Andreopoulos</surname><given-names>A</given-names></name><name><surname>Konstantopoulos</surname><given-names>K</given-names></name><article-title>Guillain-Barre syndrome presenting with sensory disturbance following a herpes virus infection: a case report</article-title><source>J Med Case Rep</source><year>2011</year><volume>5</volume><fpage>563</fpage><pub-id pub-id-type="pmid">22136568</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_021"><label>21</label><element-citation publication-type="journal" publication-format="print"><name><surname>Wachira</surname><given-names>VK</given-names></name><name><surname>Peixoto</surname><given-names>HM</given-names></name><name><surname>de Oliveira</surname><given-names>MRF</given-names></name><article-title>Systematic review of factors associated with the development of Guillain-Barre syndrome 2007&#x02013;2017: what has changed?</article-title><source>Trop Med Int Health</source><year>2019</year><volume>24</volume><fpage>132</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">30444562</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_022"><label>22</label><element-citation publication-type="journal" publication-format="print"><name><surname>Javanian</surname><given-names>M</given-names></name><name><surname>Masrour-Roudsari</surname><given-names>J</given-names></name><name><surname>Ebrahimpour</surname><given-names>S</given-names></name><article-title>Clinical diagnosis challenges in Zika virus infection</article-title><source>Caspian J Intern Med</source><year>2018</year><volume>9</volume><fpage>416</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">30510661</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_023"><label>23</label><element-citation publication-type="journal" publication-format="print"><name><surname>Vellozzi</surname><given-names>C</given-names></name><name><surname>Iqbal</surname><given-names>S</given-names></name><name><surname>Broder</surname><given-names>K</given-names></name><article-title>Guillain-Barr&#x000e9; Syndrome, Influenza, and Influenza Vaccination: The Epidemiologic Evidence</article-title><source>Clin Infect Dis</source><year>2014</year><volume>58</volume><fpage>1149</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">24415636</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_024"><label>24</label><element-citation publication-type="journal" publication-format="print"><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Shirai</surname><given-names>A</given-names></name><name><surname>Nakazawa</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><etal/><article-title>Immune Response Induced by Airway Sensitization after Influenza A Virus Infection Depends on Timing of Antigen Exposure in Mice</article-title><source>J Virol</source><year>2001</year><volume>75</volume><fpage>499</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">11119618</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_025"><label>25</label><element-citation publication-type="journal" publication-format="print"><name><surname>Martini</surname><given-names>R</given-names></name><name><surname>Willison</surname><given-names>H</given-names></name><article-title>Neuroinflammation in the peripheral nerve: Cause, modulator, or bystander in peripheral neuropathies?</article-title><source>Glia</source><year>2016</year><volume>64</volume><fpage>475</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">26250643</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_026"><label>26</label><element-citation publication-type="journal" publication-format="print"><name><surname>Ydens</surname><given-names>E</given-names></name><name><surname>Cauwels</surname><given-names>A</given-names></name><name><surname>Asselbergh</surname><given-names>B</given-names></name><name><surname>Goethals</surname><given-names>S</given-names></name><name><surname>Peeraer</surname><given-names>L</given-names></name><name><surname>Lornet</surname><given-names>G</given-names></name><etal/><article-title>Acute injury in the peripheral nervous system triggers an alternative macrophage response</article-title><source>J Neuroinflammation</source><year>2012</year><volume>9</volume><fpage>176</fpage><pub-id pub-id-type="pmid">22818207</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_027"><label>27</label><element-citation publication-type="journal" publication-format="print"><name><surname>Yuki</surname><given-names>N</given-names></name><article-title>Guillain-Barr&#x000e9; syndrome and anti-ganglioside antibodies: a clinician-scientist&#x02019;s journey</article-title><source>Proc Jpn Acad Ser B Phys Biol Sci</source><year>2012</year><volume>88</volume><fpage>299</fpage><lpage>326</lpage></element-citation></ref><ref id="j_jtim-2019-0028_ref_028"><label>28</label><element-citation publication-type="journal" publication-format="print"><name><surname>Wanschitz</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>H</given-names></name><name><surname>Lassmann</surname><given-names>H</given-names></name><name><surname>Budka</surname><given-names>H</given-names></name><name><surname>Berger</surname><given-names>T</given-names></name><article-title>Distinct time pattern of complement activation and cytotoxic T cell response in Guillain&#x02013;Barr&#x000e9; syndrome</article-title><source>Brain</source><year>2003</year><volume>126</volume><fpage>2034</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">12847075</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_029"><label>29</label><element-citation publication-type="journal" publication-format="print"><name><surname>Javanian</surname><given-names>M</given-names></name><name><surname>Babazadeh</surname><given-names>A</given-names></name><name><surname>Ebrahimpour</surname><given-names>S</given-names></name><name><surname>Shokri</surname><given-names>M</given-names></name><name><surname>Bayani</surname><given-names>M</given-names></name><article-title>Clinical and laboratory findings of patients with the possible diagnosis of influenza hospitalized in affiliated hospitals of Babol University of Medical Sciences, 2015&#x02013;2016</article-title><source>Current Issues in Pharmacy and Medical Sciences</source><year>2018</year><volume>31</volume><fpage>113</fpage><lpage>16</lpage></element-citation></ref><ref id="j_jtim-2019-0028_ref_030"><label>30</label><element-citation publication-type="journal" publication-format="print"><name><surname>ZABLOCKIEN&#x00116;</surname><given-names>B</given-names></name><name><surname>KA&#x0010c;ERGIUS</surname><given-names>T</given-names></name><name><surname>AMBROZAITIS</surname><given-names>A</given-names></name><name><surname>&#x0017d;URAUSKAS</surname><given-names>E</given-names></name><name><surname>BRATCHIKOV</surname><given-names>M</given-names></name><name><surname>JURGAUSKIEN&#x00116;</surname><given-names>L</given-names></name><etal/><article-title>Zanamivir Diminishes Lung Damage in Influenza A Virus-infected Mice by Inhibiting Nitric Oxide Production</article-title><source>In Vivo</source><year>2018</year><volume>32</volume><fpage>473</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">29695548</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_031"><label>31</label><element-citation publication-type="journal" publication-format="print"><name><surname>Schmidt</surname><given-names>ME</given-names></name><name><surname>Varga</surname><given-names>SM</given-names></name><article-title>The CD8 T Cell Response to Respiratory Virus Infections</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>678</fpage><pub-id pub-id-type="pmid">29686673</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_032"><label>32</label><element-citation publication-type="journal" publication-format="print"><name><surname>Glezen</surname><given-names>WP</given-names></name><article-title>Clinical practice. Prevention and treatment of seasonal influenza</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>2579</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">19073977</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_033"><label>33</label><element-citation publication-type="journal" publication-format="print"><name><surname>Paules</surname><given-names>C</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name><article-title>Influenza</article-title><source>The Lancet</source><year>2017</year><volume>390</volume><fpage>697</fpage><lpage>708</lpage></element-citation></ref><ref id="j_jtim-2019-0028_ref_034"><label>34</label><element-citation publication-type="journal" publication-format="print"><name><surname>van den Dool</surname><given-names>C</given-names></name><name><surname>Hak</surname><given-names>E</given-names></name><name><surname>Wallinga</surname><given-names>J</given-names></name><name><surname>van Loon</surname><given-names>AM</given-names></name><name><surname>Lammers</surname><given-names>JW</given-names></name><name><surname>Bonten</surname><given-names>MJ</given-names></name><article-title>Symptoms of influenza virus infection in hospitalized patients</article-title><source>Infect Control Hosp Epidemiol</source><year>2008</year><volume>29</volume><fpage>314</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18462143</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_035"><label>35</label><element-citation publication-type="journal" publication-format="print"><name><surname>Pleschka</surname><given-names>S</given-names></name><article-title>Overview of influenza viruses</article-title><source>Curr Top Microbiol Immunol</source><year>2013</year><volume>370</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">23124938</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_036"><label>36</label><element-citation publication-type="journal" publication-format="print"><name><surname>Smith</surname><given-names>DB</given-names></name><name><surname>Gaunt</surname><given-names>ER</given-names></name><name><surname>Digard</surname><given-names>P</given-names></name><name><surname>Templeton</surname><given-names>K</given-names></name><name><surname>Simmonds</surname><given-names>P</given-names></name><article-title>Detection of influenza C virus but not influenza D virus in Scottish respiratory samples</article-title><source>J Clin Virol</source><year>2016</year><volume>74</volume><fpage>50</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">26655269</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_037"><label>37</label><element-citation publication-type="journal" publication-format="print"><name><surname>Taubenberger</surname><given-names>JK</given-names></name><name><surname>Kash</surname><given-names>JC</given-names></name><article-title>Influenza Virus Evolution, Host Adaptation and Pandemic Formation</article-title><source>Cell Host Microbe</source><year>2010</year><volume>7</volume><fpage>440</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">20542248</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_038"><label>38</label><element-citation publication-type="journal" publication-format="print"><name><surname>Sullivan</surname><given-names>SJ</given-names></name><name><surname>Jacobson</surname><given-names>RM</given-names></name><name><surname>Dowdle</surname><given-names>WR</given-names></name><name><surname>Poland</surname><given-names>GA</given-names></name><article-title>2009 H1N1 influenza</article-title><source>Mayo Clin Proc</source><year>2010</year><volume>85</volume><fpage>64</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">20007905</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_039"><label>39</label><element-citation publication-type="journal" publication-format="print"><name><surname>Peltola</surname><given-names>VT</given-names></name><name><surname>Boyd</surname><given-names>KL</given-names></name><name><surname>McAuley</surname><given-names>JL</given-names></name><name><surname>Rehg</surname><given-names>JE</given-names></name><name><surname>McCullers</surname><given-names>JA</given-names></name><article-title>Bacterial Sinusitis and Otitis Media following Influenza Virus Infection in Ferrets</article-title><source>Infect Immun</source><year>2006</year><volume>74</volume><fpage>2562</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16622191</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_040"><label>40</label><element-citation publication-type="journal" publication-format="print"><name><surname>Vardakas</surname><given-names>KZ</given-names></name><name><surname>Theocharis</surname><given-names>G</given-names></name><name><surname>Tansarli</surname><given-names>GS</given-names></name><name><surname>Rafailidis</surname><given-names>P</given-names></name><name><surname>Falagas</surname><given-names>ME</given-names></name><article-title>Impact of oseltamivir use on the reduction of complications in patients with influenza: a prospective study</article-title><source>Arch Virol</source><year>2016</year><volume>161</volume><fpage>2511</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">27368992</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_041"><label>41</label><element-citation publication-type="journal" publication-format="print"><name><surname>Ukimura</surname><given-names>A</given-names></name><name><surname>Satomi</surname><given-names>H</given-names></name><name><surname>Ooi</surname><given-names>Y</given-names></name><name><surname>Kanzaki</surname><given-names>Y</given-names></name><article-title>Myocarditis Associated with Influenza A H1N1pdm2009</article-title><source>Influenza Res Treat</source><year>2012</year><volume>2012</volume><comment>351979</comment></element-citation></ref><ref id="j_jtim-2019-0028_ref_042"><label>42</label><element-citation publication-type="journal" publication-format="print"><name><surname>Newland</surname><given-names>JG</given-names></name><name><surname>Romero</surname><given-names>JR</given-names></name><name><surname>Varman</surname><given-names>M</given-names></name><name><surname>Drake</surname><given-names>C</given-names></name><name><surname>Holst</surname><given-names>A</given-names></name><name><surname>Safranek</surname><given-names>T</given-names></name><etal/><article-title>Encephalitis Associated with Influenza B Virus Infection in 2 Children and a Review of the Literature</article-title><source>Clin Infect Dis</source><year>2003</year><volume>36</volume><fpage>e87</fpage><lpage>e95</lpage><pub-id pub-id-type="pmid">12652406</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_043"><label>43</label><element-citation publication-type="journal" publication-format="print"><name><surname>Fadila</surname><given-names>MF</given-names></name><name><surname>Wool</surname><given-names>KJ</given-names></name><article-title>Rhabdomyolysis Secondary to Influenza A Infection: A Case Report and Review of the Literature</article-title><source>N Am J Med Sci</source><year>2015</year><volume>7</volume><fpage>122</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">25839005</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_044"><label>44</label><element-citation publication-type="journal" publication-format="print"><name><surname>Broadbent</surname><given-names>AJ</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name><article-title>Influenza Virus Vaccines: Lessons from the 2009 H1N1 pandemic</article-title><source>Curr Opin Virol</source><year>2011</year><volume>1</volume><fpage>254</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">22125588</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_045"><label>45</label><element-citation publication-type="journal" publication-format="print"><name><surname>Sridhar</surname><given-names>S</given-names></name><name><surname>Brokstad</surname><given-names>KA</given-names></name><name><surname>Cox</surname><given-names>RJ</given-names></name><article-title>Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines</article-title><source>Vaccines (Basel)</source><year>2015</year><volume>3</volume><fpage>373</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">26343192</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_046"><label>46</label><element-citation publication-type="journal" publication-format="print"><name><surname>Tamura</surname><given-names>S</given-names></name><name><surname>Ainai</surname><given-names>A</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Kurata</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name><article-title>Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?</article-title><source>Jpn J Infect Dis</source><year>2016</year><volume>69</volume><fpage>165</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">27212584</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_047"><label>47</label><element-citation publication-type="journal" publication-format="print"><name><surname>Christian</surname><given-names>LM</given-names></name><name><surname>Porter</surname><given-names>K</given-names></name><name><surname>Karlsson</surname><given-names>E</given-names></name><name><surname>Schultz-Cherry</surname><given-names>S</given-names></name><article-title>Proinflammatory cytokine responses correspond with subjective side effects after influenza virus vaccination</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>3360</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">26027906</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_048"><label>48</label><element-citation publication-type="journal" publication-format="print"><name><surname>Coleman</surname><given-names>BL</given-names></name><name><surname>McNeil</surname><given-names>SA</given-names></name><name><surname>Langley</surname><given-names>JM</given-names></name><name><surname>Halperin</surname><given-names>SA</given-names></name><name><surname>McGeer</surname><given-names>AJ</given-names></name><article-title>Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>6635</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">26529074</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_049"><label>49</label><element-citation publication-type="journal" publication-format="print"><name><surname>Urayoshi</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>S</given-names></name><name><surname>Miyatani</surname><given-names>H</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><article-title>A case of myositis of the deltoid muscle of the upper arm developing 1 week after influenza vaccination: case report</article-title><source>Clin Case Rep</source><year>2015</year><volume>3</volume><fpage>135</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">25838900</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_050"><label>50</label><element-citation publication-type="journal" publication-format="print"><name><surname>Souayah</surname><given-names>N</given-names></name><name><surname>Yacoub</surname><given-names>HA</given-names></name><name><surname>Khan</surname><given-names>HM</given-names></name><name><surname>Farhad</surname><given-names>K</given-names></name><name><surname>Mehyar</surname><given-names>LS</given-names></name><name><surname>Maybodi</surname><given-names>L</given-names></name><etal/><article-title>Guillain-Barre syndrome after influenza vaccination in the United States, a report from the CDC/FDA vaccine adverse event reporting system (1990&#x02013;2009)</article-title><source>J Clin Neuromuscul Dis</source><year>2012</year><volume>14</volume><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">23172385</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_051"><label>51</label><element-citation publication-type="journal" publication-format="print"><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>KJ</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>KM</given-names></name><name><surname>Suh</surname><given-names>BC</given-names></name><article-title>Clinical Features of Post-Vaccination Guillain-Barr&#x000e9; Syndrome (GBS) in Korea</article-title><source>J Korean Med Sci</source><year>2017</year><volume>32</volume><fpage>1154</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">28581273</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_052"><label>52</label><element-citation publication-type="journal" publication-format="print"><name><surname>Sencer</surname><given-names>DJ</given-names></name><name><surname>Millar</surname><given-names>JD</given-names></name><article-title>Reflections on the 1976 swine flu vaccination program</article-title><source>Emerg Infect Dis</source><year>2006</year><volume>12</volume><fpage>29</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">16494713</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_053"><label>53</label><element-citation publication-type="journal" publication-format="print"><name><surname>Kwong</surname><given-names>JC</given-names></name><name><surname>Vasa</surname><given-names>PP</given-names></name><name><surname>Campitelli</surname><given-names>MA</given-names></name><name><surname>Hawken</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>K</given-names></name><name><surname>Rosella</surname><given-names>LC</given-names></name><etal/><article-title>Risk of Guillain-Barre syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study</article-title><source>Lancet Infect Dis</source><year>2013</year><volume>13</volume><fpage>769</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">23810252</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_054"><label>54</label><element-citation publication-type="journal" publication-format="print"><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>KJ</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>KM</given-names></name><name><surname>Suh</surname><given-names>BC</given-names></name><article-title>Clinical Features of Post-Vaccination Guillain-Barr&#x000e9; Syndrome (GBS) in Korea</article-title><source>J Korean Med Sci</source><year>2017</year><volume>32</volume><fpage>1154</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">28581273</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_055"><label>55</label><element-citation publication-type="journal" publication-format="print"><name><surname>Polakowski</surname><given-names>LL</given-names></name><name><surname>Sandhu</surname><given-names>SK</given-names></name><name><surname>Martin</surname><given-names>DB</given-names></name><name><surname>Ball</surname><given-names>R</given-names></name><name><surname>MaCurdy</surname><given-names>TE</given-names></name><name><surname>Franks</surname><given-names>RL</given-names></name><etal/><article-title>Chart-Confirmed Guillain-Barr&#x000e9; Syndrome After 2009 H1N1 Influenza Vaccination Among the Medicare Population, 2009&#x02013;2010</article-title><source>Am J Epidemiol</source><year>2013</year><volume>178</volume><fpage>962</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">23652165</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_056"><label>56</label><element-citation publication-type="journal" publication-format="print"><name><surname>Sivadon-Tardy</surname><given-names>V</given-names></name><name><surname>Orlikowski</surname><given-names>D</given-names></name><name><surname>Porcher</surname><given-names>R</given-names></name><name><surname>Sharshar</surname><given-names>T</given-names></name><name><surname>Durand</surname><given-names>M-C</given-names></name><name><surname>Enouf</surname><given-names>V</given-names></name><etal/><article-title>Guillain-Barr&#x000e9; Syndrome and Influenza Virus Infection</article-title><source>Clin Infect Dis</source><year>2009</year><volume>48</volume><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">19025491</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_057"><label>57</label><element-citation publication-type="journal" publication-format="print"><name><surname>Sellers</surname><given-names>SA</given-names></name><name><surname>Hagan</surname><given-names>RS</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name><name><surname>Fischer</surname><given-names>WA</given-names><suffix>2nd</suffix></name><article-title>The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection</article-title><source>Influenza Other Respir Viruses</source><year>2017</year><volume>11</volume><fpage>372</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">28745014</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_058"><label>58</label><element-citation publication-type="journal" publication-format="print"><name><surname>Ghaderi</surname><given-names>S</given-names></name><name><surname>Gunnes</surname><given-names>N</given-names></name><name><surname>Bakken</surname><given-names>IJ</given-names></name><name><surname>Magnus</surname><given-names>P</given-names></name><name><surname>Trogstad</surname><given-names>L</given-names></name><name><surname>Haberg</surname><given-names>SE</given-names></name><article-title>Risk of Guillain-Barre syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study</article-title><source>Eur J Epidemiol</source><year>2016</year><volume>31</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">26008750</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_059"><label>59</label><element-citation publication-type="journal" publication-format="print"><name><surname>Wang</surname><given-names>DJ</given-names></name><name><surname>Boltz</surname><given-names>DA</given-names></name><name><surname>McElhaney</surname><given-names>J</given-names></name><name><surname>McCullers</surname><given-names>JA</given-names></name><name><surname>Webby</surname><given-names>RJ</given-names></name><name><surname>Webster</surname><given-names>RG</given-names></name><article-title>No evidence of a link between influenza vaccines and Guillain-Barre syndrome-associated antiganglioside antibodies</article-title><source>Influenza Other Respir Viruses</source><year>2012</year><volume>6</volume><fpage>159</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">21955390</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_060"><label>60</label><element-citation publication-type="journal" publication-format="print"><name><surname>Souayah</surname><given-names>N</given-names></name><name><surname>Yacoub</surname><given-names>HA</given-names></name><name><surname>Khan</surname><given-names>HMR</given-names></name><name><surname>Michas-Martin</surname><given-names>PA</given-names></name><name><surname>Menkes</surname><given-names>DL</given-names></name><name><surname>Maybodi</surname><given-names>L</given-names></name><etal/><article-title>Guillain-Barr&#x000e9; Syndrome after H1N1 Vaccination in the United States: A Report Using the CDC/FDA Vaccine Adverse Event Reporting System (2009)</article-title><source>Neuroepidemiology</source><year>2012</year><volume>38</volume><fpage>227</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">22555646</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_061"><label>61</label><element-citation publication-type="journal" publication-format="print"><name><surname>Mathew</surname><given-names>T</given-names></name><name><surname>Srinivas</surname><given-names>M</given-names></name><name><surname>Nadig</surname><given-names>R</given-names></name><name><surname>Arumugam</surname><given-names>R</given-names></name><name><surname>Sarma</surname><given-names>GRK</given-names></name><article-title>Seasonal and monthly trends in the occurrence of Guillain-Barre syndrome over a 5-year period: A tertiary care hospital-based study from South India</article-title><source>Ann Indian Acad Neurol</source><year>2014</year><volume>17</volume><fpage>239</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">25024587</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_062"><label>62</label><element-citation publication-type="journal" publication-format="print"><name><surname>McCarthy</surname><given-names>EA</given-names></name><name><surname>Pollock</surname><given-names>WE</given-names></name><name><surname>Tapper</surname><given-names>L</given-names></name><name><surname>Sommerville</surname><given-names>M</given-names></name><name><surname>McDonald</surname><given-names>S</given-names></name><article-title>Increasing uptake of influenza vaccine by pregnant women post H1N1 pandemic: a longitudinal study in Melbourne, Australia, 2010 to 2014</article-title><source>BMC Pregnancy Childbirth</source><year>2015</year><volume>15</volume><fpage>53</fpage><pub-id pub-id-type="pmid">25880530</pub-id></element-citation></ref><ref id="j_jtim-2019-0028_ref_063"><label>63</label><element-citation publication-type="journal" publication-format="print"><name><surname>Nakagawa</surname><given-names>N</given-names></name><name><surname>Higashi</surname><given-names>N</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name><article-title>Cocirculation of Antigenic Variants and the Vaccine-Type Virus during the 2004&#x02013;2005 Influenza B Virus Epidemics in Japan</article-title><source>J Clin Microbiol</source><year>2009</year><volume>47</volume><fpage>352</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19091818</pub-id></element-citation></ref></ref-list></back></article>